系统的多领域阿尔茨海默氏症降低风险试验 (SMARRT) 干预:个性化的方法来降低痴呆风险
Deborah E Barnes1,2, Benjamin H Balderson3, Lisa Shulman3
1Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Journal of Alzheimer's disease : JAD
|December 3, 2024
概括
患阿尔茨海默病风险较高的老年人为减少痴呆风险设定了个性化的目标. 一种灵活的方法,支持和可管理的目标被证明是有效的.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 可修改的风险因素,如身体不活动和社会隔离,可能会降低阿尔茨海默病 (AD) 和痴呆风险.
- 了解个人处理这些风险因素的意愿和偏好对于有效的干预至关重要.
研究的目的:
- 检查和描述由系统多域阿尔茨海默氏症风险降低试验 (SMARRT) 参与者建立的行为改变目标.
主要方法:
- 在SMARRT试验中,老年人与健康教练和护士一起工作了两年,为减少痴呆风险设定了个性化的增量目标.
- 定量分析总结了每个风险因素的目标数字,而笔记的定性内容分析描述了目标类型和有效策略.
主要成果:
- 参与者 (n=82,年龄在70-89岁) 经常针对体力活动 (95%),高血压 (72%) 和认知活动 (60%) 降低风险.
- 参与者报告说,健康教练/护士支持,问责制,设定小目标和管理挫折是非常有效的策略.
结论:
- 患有痴呆症风险增加的老年人,在得到支持的情况下,为降低风险制定各种目标.
- 一个个性化,灵活的战略,专注于可行的目标和挫折管理,为减少痴呆风险提供了一个有价值的框架.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.1K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
